A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Thrombosis Research

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2012.02.035PMID 22405050PMCID PMC3928126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post‐transfusion elimination time of canine factor IX in hemophilia B dogs

  2012cited by this paper
• Porcine and Canine von Willebrand Factor and von Willebrand Disease: Hemostasis, Thrombosis, and Atherosclerosis Studies

  2011cited by this paper
• Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

  2011cited by this paper
• ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.

  2011cited by this paper
• Merry christmas for patients with hemophilia B.

  2011cited by this paper
• Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

  2009cited by this paper
• Emergency reversal of antithrombotic treatment

  2009cited by this paper
• Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

  2009cited by this paper
• ARFI Ultrasound for In Vivo Hemostasis Assessment Postcardiac Catheterization, Part II: Pilot Clinical Results

  2009cited by this paper
• What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008.

  2008cited by this paper
• Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia.

  2008cited by this paper
• Porcine von Willebrand Disease and Atherosclerosis Influence of Polymorphism in Apolipoprotein B100 Genotype hypercholesterolemia and atherosclerotic plaque formation in vWD and normal swine without the

  2007cited by this paper
• Use of recombinant factor VIIa for emergency reversal of anticoagulation.

  2007cited by this paper
• Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

  2006cited by this paper
• Haemophilia A in two premature infants

  2005cited by this paper
• Effectiveness and safety of manual hemostasis facilitated by the SyvekPatch with one hour of bedrest after coronary angiography using six-French catheters.

  2004cited by this paper
• Molecular basis of haemophilia A

  2004cited by this paper
• New high‐technology products for the treatment of haemophilia

  2004cited by this paper
• Surgery in haemophilic patients with inhibitor: 20 years of experience

  2004cited by this paper
• Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1

  2004cited by this paper
• Evaluation of poly-N-acetyl glucosamine as a hemostatic agent in patients undergoing cardiac catheterization: a double-blind, randomized study.

  2004cited by this paper
• Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.

  2002cited by this paper
• Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility.

  2002cited by this paper
• Clinical evaluation of SyvekPatch in patients undergoing interventional, EPS and diagnostic cardiac catheterization procedures.

  2002cited by this paper
• Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

  1996cited by this paper
• The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A.

  1993cited by this paper
• Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype.

  1992cited by this paper
• Evaluation of the Buccal Bleeding Time and Platelet Glass Bead Retention as Assays of Hemostasis in the Dog: The Effects of Acetylsalicylic Acid, Warfarin and von Willebrand Factor Deficiency

  1991cited by this paper
• Hemophilia treatment in historical perspective: a review of medical and social developments

  1991cited by this paper
• A Critical Reappraisal of the Bleeding Time*

  1990cited by this paper
• Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

  1989cited by this paper
• In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).

  1988influential reference
• Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease.

  1987cited by this paper
• Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

  1985cited by this paper
• A canine model of hemophilic (factor VIII:C deficiency) bleeding.

  1982influential reference
• Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions.

  1981cited by this paper
• Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

  1953cited by this paper
• THE ANOMALY OF A NORMAL DUKE'S AND A VERY PROLONGED SALINE BLEEDING TIME IN SWINE SUFFERING FROM AN INHERITED BLEEDING DISEASE

  1942cited by this paper
• A CLINICAL STUDY OF THE COAGULATION TIME OF BLOOD

  1913cited by this paper

• Improving the adhesion, flexibility, and hemostatic efficacy of a sprayable polymer blend surgical sealant by incorporating silica particles.

  2019cites this paper
• Acoustic Radiation Force Impulse Ultrasound

  2018cites this paper
• Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs

  2016cites this paper
• Adsorption of tranexamic acid on hydroxyapatite: Toward the development of biomaterials with local hemostatic activity.

  2016cites this paper
• Improving Displacement Signal-to-Noise Ratio for Low-Signal Radiation Force Elasticity Imaging Using Bayesian Techniques.

  2016cites this paper
• Lessons Learned from Animal Models of Inherited Bleeding Disorders.

  2014cites this paper
• HEMATOPOIETIC GROWTH AND COAGULATION FACTORS

  2013cites this paper
• ARFI-Monitored Hemostatic Challenge for Assessment of In Vivo Hemostasis in Canine Models of Inherited Bleeding Disorders

  2012influential citation